Last reviewed · How we verify
ARS-1
ARS-1 is a small molecule that targets the [insert target here, if known].
ARS-1 is a small molecule that targets the [insert target here, if known]. Used for Phase 2 for [insert indication here, if known].
At a glance
| Generic name | ARS-1 |
|---|---|
| Sponsor | ARS Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
ARS-1 works by [insert explanation here, if known].
Approved indications
- Phase 2 for [insert indication here, if known]
Common side effects
Key clinical trials
- Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares (PHASE2)
- NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions (PHASE3)
- Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma (PHASE2)
- Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARS-1 CI brief — competitive landscape report
- ARS-1 updates RSS · CI watch RSS
- ARS Pharmaceuticals, Inc. portfolio CI